このエントリーをはてなブックマークに追加
ID 52029
フルテキストURL
著者
Wada, Tadashi Department of Cardiology, Fukuyama City Hospital
Nakahama, Makoto Department of Cardiology, Fukuyama City Hospital
Toda, Hironobu Department of Cardiology, Fukuyama City Hospital
Watanabe, Atsuyuki Department of Cardiology, Fukuyama City Hospital
Hashimoto, Katsushi Department of Cardiology, Fukuyama City Hospital
Terasaka, Ritsuko Department of Cardiology, Fukuyama City Hospital
Nakamura, Kazufumi Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamada, Nobuyuki Department of Cardiology, Fukuyama City Hospital
Ito, Hiroshi Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
抄録
Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention increases the risk of bleeding. We studied the safety and clinical outcomes of switching from DAPT to aspirin monotherapy at 3 months after ZES implantation. We retrospectively evaluated 168 consecutive patients with coronary artery disease who had been implanted with a ZES from June 2009 through March 2010. After excluding 40 patients according to exclusion criteria such as myocardial infarction, 128 patients were divided into a 3-month DAPT group (67 patients, 88 lesions) and a 12-month conventional DAPT group (61 patients, 81 lesions). Coronary angiographic followup and clinical followup were conducted at more than 8 months and at 12 months after ZES implantation, respectively. Minor and major bleeding events, stent thrombosis (ST), and major adverse cardiac events (MACE) (death, myocardial infarction, cerebrovascular accident, target lesion revascularization, and target vessel revascularization) were evaluated. There were no statistically significant differences in the incidences of ST and MACE between the two groups. The incidence of bleeding events was significantly lower in the 3-month group than in the 12-month group (1.5% versus 11.5%, ). DAPT can be safely discontinued at 3 months after ZES implantation, which reduces bleeding risk.
発行日
2013
出版物タイトル
ISRN Cardiology
2013巻
出版者
Hindawi Publishing Corporation
資料タイプ
学術雑誌論文
オフィシャル URL
http://dx.doi.org/10.1155/2013/518968
関連URL
http://ousar.lib.okayama-u.ac.jp/metadata/51960
言語
English
OAI-PMH Set
岡山大学
著作権者
© 2013 Tadashi Wada et al.
論文のバージョン
publisher
査読
有り
DOI